These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38305113)

  • 1. Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
    Mogilevski T; Nguyen AL; Ajamian M; Smith R; Rosella S; Sparrow MP; Moore GT; Gibson PR
    Eur J Gastroenterol Hepatol; 2024 Mar; 36(3):271-280. PubMed ID: 38305113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease.
    Pastor Rojo O; López San Román A; Albéniz Arbizu E; de la Hera Martínez A; Ripoll Sevillano E; Albillos Martínez A
    Inflamm Bowel Dis; 2007 Mar; 13(3):269-77. PubMed ID: 17206721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.
    Lakatos PL; Kiss LS; Palatka K; Altorjay I; Antal-Szalmas P; Palyu E; Udvardy M; Molnar T; Farkas K; Veres G; Harsfalvi J; Papp J; Papp M
    Inflamm Bowel Dis; 2011 Mar; 17(3):767-77. PubMed ID: 20865702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASE.
    Lacombe LAC; Matiollo C; Rosa JSD; Felisberto M; Dalmarco EM; Schiavon LL
    Arq Gastroenterol; 2022; 59(2):238-243. PubMed ID: 35830035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.
    Hosomi S; Yamagami H; Itani S; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    J Crohns Colitis; 2018 Jan; 12(1):87-95. PubMed ID: 28961693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial.
    Rath T; Atreya R; Bodenschatz J; Uter W; Geppert CE; Vitali F; Fischer S; Waldner MJ; Colombel JF; Hartmann A; Neurath MF
    Gastroenterology; 2023 Feb; 164(2):241-255. PubMed ID: 36279923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
    Bodelier AG; Pierik MJ; Lenaerts K; de Boer E; Olde Damink SW; Hameeteman WM; Masclee AA; Jonkers DM
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):807-13. PubMed ID: 26919325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease.
    Vitali R; Palone F; Armuzzi A; Fulci V; Negroni A; Carissimi C; Cucchiara S; Stronati L
    J Crohns Colitis; 2023 Jan; 17(1):92-102. PubMed ID: 36040453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.
    Michelini Z; Baroncelli S; Fantauzzi A; Pasquale C; Galluzzo CM; Sanchez M; Gatto M; Amici R; Franco M; d'Ettorre G; Fimiani C; Mezzaroma I; Vullo V; Merli M; Palmisano L
    HIV Clin Trials; 2016 Mar; 17(2):49-54. PubMed ID: 26739837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
    Wen N; Zhao N; Xu H; Zhao Y; Ma J
    Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of biomarkers of intestinal barrier function in response to a high fat/high carbohydrate meal and corticotropin releasing hormone.
    Mogilevski T; Rosella S; Nguyen A; Fitzpatrick J; Parker F; Halmos EP; Gibson PR
    PLoS One; 2024; 19(2):e0294918. PubMed ID: 38408050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.
    Hisamatsu T; Okamoto S; Hashimoto M; Muramatsu T; Andou A; Uo M; Kitazume MT; Matsuoka K; Yajima T; Inoue N; Kanai T; Ogata H; Iwao Y; Yamakado M; Sakai R; Ono N; Ando T; Suzuki M; Hibi T
    PLoS One; 2012; 7(1):e31131. PubMed ID: 22303484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble syndecan-1 as marker of intestinal inflammation: A preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis.
    Floer M; Clausen M; Meister T; Vollenberg R; Bettenworth D; Tepasse PR
    Adv Clin Exp Med; 2021 Jul; 30(7):655-660. PubMed ID: 34286513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease.
    Baumgart DC; Thomas S; Przesdzing I; Metzke D; Bielecki C; Lehmann SM; Lehnardt S; Dörffel Y; Sturm A; Scheffold A; Schmitz J; Radbruch A
    Clin Exp Immunol; 2009 Sep; 157(3):423-36. PubMed ID: 19664152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of confocal laser endomicroscopy for assessment and monitoring of therapeutic response in patients with inflammatory bowel disease.
    Karstensen JG
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.
    Pasternak BA; D'Mello S; Jurickova II; Han X; Willson T; Flick L; Petiniot L; Uozumi N; Divanovic S; Traurnicht A; Bonkowski E; Kugathasan S; Karp CL; Denson LA
    Inflamm Bowel Dis; 2010 May; 16(5):856-69. PubMed ID: 19924809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn's disease: Correlations with disease activity, extent, and location.
    Abdelazim SA; Shaker OG; Ali O; El-Tawil M; Senousy MA
    Pathol Res Pract; 2023 Dec; 252():154910. PubMed ID: 37939427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease.
    Logan M; MacKinder M; Clark CM; Kountouri A; Jere M; Ijaz UZ; Hansen R; McGrogan P; Russell RK; Gerasimidis K
    BMC Gastroenterol; 2022 May; 22(1):260. PubMed ID: 35606704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.